Education
About Us
Working with TipRanks
Follow Us
Cellectis SA (CLLS)
NASDAQ:CLLS
Top Page
Cellectis SA
(NASDAQ:CLLS)
Rating:64Neutral
Price Target:
$2.50
▼(-6.37% Downside)
Positive Factors
Cash Position
Management anticipates that the cash position is strong, with approximately $246 million in cash, cash equivalents, restricted cash, and fixed-term deposits.
Clinical Trials
Cellectis is on track to initiate a pivotal Phase 2 trial for lasme-cel in relapsed/refractory B-ALL.
Partnerships
Cellectis is making substantial progress across its clinical programs following a pipeline overhaul and strategic investment by AstraZeneca.
Negative Factors
Conflicts of Interest
Investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report.
Data Updates
Cellectis has guided for data updates from Phase 1 trials, but durability data in larger cohorts is needed to have confidence in the assets.
Financial Performance
Net loss per share was ($0.18) versus consensus of ($0.15).
Cellectis SA (CLLS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$191.23M
Dividend YieldN/A
Average Volume (3M)218.24K
Price to Earnings (P/E)―
Beta (1Y)3.13
Revenue Growth333.74%
EPS GrowthN/A
CountryUS
Employees216
SectorHealthcare
Sector Strength47
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.24
Shares Outstanding72,093,636
10 Day Avg. Volume93,565
30 Day Avg. Volume218,237
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.24
Price to Sales (P/S)3.93
P/FCF Ratio8.51
Enterprise Value/Market Cap0.36
Enterprise Value/Revenue1.22
Enterprise Value/Gross Profit1.77
Enterprise Value/Ebitda-1.93
Forecast
1Y Price Target
$2.50Price Target Upside-6.37% Downside
Rating ConsensusHold
Number of Analyst Covering2
Cellectis SA Business Overview & Revenue Model
Company DescriptionCellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
How the Company Makes MoneyCellectis generates revenue through a combination of partnerships, collaborations, and licensing agreements with pharmaceutical and biotechnology companies. The company primarily earns money by entering into strategic alliances that provide funding for research and development in exchange for rights to commercialize its gene-editing technologies and products. Additionally, Cellectis may receive milestone payments and royalties based on the commercial success of therapies developed using its technologies. Significant partnerships with major players in the pharmaceutical industry contribute to its revenue streams, as well as potential advancements in clinical trials that lead to further business opportunities.
Cellectis SA Earnings Call Summary
Earnings Call Date:Aug 04, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Nov 10, 2025
Earnings Call Sentiment Positive
The earnings call reflects a generally positive sentiment, driven by progress in clinical trials and strategic partnerships, despite financial and legal challenges. The successful advancement of pivotal trials and the strong collaboration with AstraZeneca are significant positives. However, the arbitration with Servier presents a notable uncertainty.Q2-2025 Updates
Positive Updates
Pivotal Phase II Trial Initiation
Cellectis is preparing to initiate a pivotal Phase II trial for lasme-cel, UCART22, in relapsed or refractory acute lymphoblastic leukemia in the second half of 2025, following successful end of Phase I discussions with the FDA and EMA.
Strategic Collaboration with AstraZeneca
Research and development activities are ongoing under the partnership with AstraZeneca, covering three cell and gene therapy programs targeting hematological malignancies, solid tumors, and a genetic disorder.
Financial Sufficiency
Cellectis reports a cash position of $230 million as of June 30, 2025, sufficient to fund operations into H2 2027, including pivotal studies for lasme-cel and eti-cel.
Expansion of Clinical Trial Sites
Cellectis is expanding clinical trial sites in the United States and Europe, including the UK, to accelerate recruitment for the Phase II study of UCART22.
Negative Updates
Servier Arbitration Uncertainty
Cellectis is involved in ongoing arbitration with Servier and Allogene, seeking to terminate the agreement and receive compensation for losses and milestone payments due to halted CD19 product development.
Decrease in Cash Reserves
There was a $33.2 million decrease in cash, cash equivalents, and fixed-term deposits from December 31, 2024, to June 30, 2025, primarily due to operating expenses.
Company Guidance
During the Cellectis Second Quarter 2025 Earnings Call, the company provided extensive guidance on several key metrics and strategic initiatives. Cellectis announced plans to host an Investor R&D Day on October 16, 2025, in New York City, where they will present Phase I data and a late-stage development strategy for lasme-cel, UCART22, in relapsed or refractory acute lymphoblastic leukemia. The pivotal Phase II trial for lasme-cel is set to begin in the second half of 2025, following productive discussions with the FDA and EMA. The company also updated on their arbitration proceedings with Servier, with a decision expected by December 15, 2025. Financially, Cellectis reported a cash position of $230 million as of June 30, 2025, sufficient to fund operations into the second half of 2027. This includes the costs associated with the pivotal studies for lasme-cel and eti-cel. Additionally, the company shared progress on their collaboration with AstraZeneca, which includes three cell and gene therapy programs.Cellectis SA Financial Statement Overview
Summary
Cellectis SA shows mixed financial health with some strengths in liquidity and cash management but ongoing challenges in profitability and revenue consistency. The balance sheet indicates a stable but declining equity position, while cash flow improvements provide a positive outlook amid persistent net losses.Income Statement
The company shows a fluctuating revenue trend, with a significant decline from 2021 to 2023, followed by a recovery in 2024 and TTM. Gross profit margin is relatively stable but net profit margin remains negative, indicating ongoing losses. EBIT and EBITDA margins are also negative, reflecting operational inefficiencies.55
Neutral
Balance Sheet
The balance sheet reveals a moderate debt-to-equity ratio, suggesting manageable leverage. The equity ratio has been declining, which might indicate increasing liabilities relative to assets. Despite this, the company maintains a solid cash position, which can be advantageous for liquidity.60
Neutral
Cash Flow
Positive developments in cash flow are noted, with operating cash flow turning positive in recent periods. The free cash flow growth is encouraging, although the company has historically faced negative free cash flows. The ratio of operating cash flow to net income is favorable, highlighting efficient cash management despite net losses.65
Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 56.51M | 41.51M | 755.00K | 19.17M | 73.95M | 73.95M |
| Gross Profit | 38.86M | 21.63M | 18.00K | 17.40M | 37.67M | 37.67M |
| EBITDA | -35.61M | -15.84M | -92.64M | -76.38M | -86.46M | -34.68M |
| Net Income | -59.30M | -36.76M | -101.06M | -98.69M | -86.28M | -72.57M |
Balance Sheet | ||||||
| Total Assets | 353.97M | 383.54M | 334.27M | 261.22M | 382.08M | 469.47M |
| Cash, Cash Equivalents and Short-Term Investments | 198.15M | 260.31M | 203.81M | 97.70M | 186.13M | 268.24M |
| Total Debt | 113.83M | 91.46M | 92.85M | 82.85M | 102.24M | 111.30M |
| Total Liabilities | 256.86M | 252.51M | 249.57M | 135.28M | 145.60M | 160.63M |
| Stockholders Equity | 97.11M | 131.03M | 84.69M | 117.97M | 221.29M | 275.57M |
Cash Flow | ||||||
| Free Cash Flow | -25.98M | 19.15M | -25.82M | -89.89M | -124.31M | -126.52M |
| Operating Cash Flow | -23.04M | 22.99M | -24.75M | -87.44M | -104.56M | -80.26M |
| Investing Cash Flow | 9.89M | -102.81M | -15.51M | -2.76M | 7.28M | -54.34M |
| Financing Cash Flow | -5.38M | 89.11M | 82.86M | 1.15M | 47.52M | 27.32M |
Cellectis SA Technical Analysis
Positive
2.67
Price Trends
2.20
Positive
1.83
Positive
1.72
Positive
Market Momentum
0.13
Positive
52.87
Neutral
9.81
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLLS, the sentiment is Positive. The current price of 2.67 is below the 20-day moving average (MA) of 2.75, above the 50-day MA of 2.20, and above the 200-day MA of 1.72, indicating a neutral trend. The MACD of 0.13 indicates Positive momentum. The RSI at 52.87 is Neutral, neither overbought nor oversold. The STOCH value of 9.81 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CLLS.
Cellectis SA Risk Analysis
Cellectis SA disclosed 102 risk factors in its most recent earnings report. Cellectis SA reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cellectis SA Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $191.23M | ― | -48.36% | ― | 333.74% | ― | |
55 Neutral | $245.48M | ― | -188.58% | ― | -41.97% | -20.86% | |
52 Neutral | $304.97M | ― | -38.87% | ― | ― | ― | |
52 Neutral | $186.25M | ― | -68.93% | ― | -72.45% | -28.60% | |
51 Neutral | $7.83B | -0.18 | -40.10% | 2.29% | 21.46% | -2.03% | |
39 Underperform | $156.96M | ― | -26.94% | ― | ― | 26.33% | |
33 Underperform | $263.50M | ― | -125.43% | ― | ― | -686.13% |
* Healthcare Sector Average
Performance Comparison
CLLS
Cellectis SA
2.67
0.30
12.66%
EDIT
Editas Medicine
2.67
-1.01
-27.45%
NKTX
Nkarta
2.24
-3.00
-57.25%
FDMT
4D Molecular Therapeutics
6.46
-8.84
-57.78%
VOR
Vor Biopharma
2.00
1.14
132.56%
CRBU
Caribou Biosciences
1.98
-0.11
-5.26%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.